Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences total stock-based compensation (SBC) expense ($M) ($M)
Form 10-Q / 10-K Note 13 Stock-Based Compensation
Latest, Q2 2026
231
Period ended Jun 30, 2026
Change on a year earlier
+2.7%
225 in Q2 2025
History
50 quarters
Since Q1 2014
Sources
38
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up total stock-based compensation (sbc) expense ($m)
- SBC expense — Cost of goods sold ($M)–
- SBC expense — Research and development ($M)–
- SBC expense — Selling, general and administrative ($M)–
- SBC income tax benefit ($M)–
- SBC expense, net of tax ($M)–
- SBC expense by award type — Restricted Stock Units (RSUs, $M)–
- SBC expense by award type — Performance Share Units (PSUs, $M)–
- SBC expense by award type — Stock Options ($M)–
- SBC expense by award type — Employee Stock Purchase Plan (ESPP, $M)–
- RSU rollforward — Nonvested shares at period-end (M shares)–
- PSU rollforward — Nonvested shares at period-end (M shares)–
Cite this data
StockData. (2026). Gilead Sciences Total stock-based compensation (SBC) expense ($M) ($M), quarterly Q1 2014–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/sbc_tot
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.